Skip to Content

E. S. Kopetz, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2009 University of Texas, Houston, TX, PhD, (anticipated), Patient Oriented Biological Research
2001 John Hopkins School of Medicine, Baltimore, MD, MD, Medicine
1997 Vanderbilt University, Nashville, TN, BE, Summa Cum Laude, Biomedical Engineering/Electrical Engineering

Postgraduate Training

7/2004-6/2006 Fellowship, Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, Robert Wolff
7/2001-6/2004 Residency, Internal Medicine, Duke University Medical Center, Durham, NC, Diana McNeil

Board Certifications

10/2006 Medical Oncology
10/2004 Internal Medicine

Selected Publications

Peer-Reviewed Original Research Articles
1. Kopetz S, Chang G, Overman M, Eng C, Larson DW, Grothey A, Vauthey JN, Sargent D, McWilliams R. Improved Survival in Metastatic Colorectal Cancer is Associated with Sequential Adoption of Hepatic Resection and Improved Chemotherapy. J Clin Oncol 27(22):3677-83, 8/2009. PMID: 19470929.
2. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res. 69(9):3842-9, 5/2009. e-Pub 4/2009. PMID: 19383922.
3. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 16(3):614-22, 03/2009, 3/2009. e-Pub 1/2009. PMID: 19130139.
4. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, Eng C, Abbruzzese JL, Wolff RA. Phase II study of Capecitabine and Oxaliplatin for Advanced Adenocarcinoma of the Small Bowel and Ampulla of Vater. J Clin Oncol 26(15S):4538, 2/2009. PMID: 19164203.
5. Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P. Sacral Insufficiency Fractures After Preoperative Chemoradiation for Rectal Cancer: Incidence, Risk Factors, and Clinical Course. Int J Radiat Oncol Biol Phys 74(3), 1/2009. PMID: 19147305.
6. Kim MP, Park SI, Kopetz S, Gallick GE. Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis. Cell Tissue Res. 1(335):249-59, 1/2009. PMID: 18815812.
7. Fogelman DR, Kopetz S, Eng C. Emerging Drugs for Colorectal Cancer. Expert Opin Emerg Drugs 13(4):629-42, 12/2008. PMID: 19046131.
8. Blazer DG, Kish U, Maru DM, Kopetz S, Overman M, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover K, Wolff RA, Curley SA, Abdalla EK, Vauthey JN. Pathologic Response to Preoperative Chemotherapy: A New Outcome End Point after Resection of Hepatic Colorectal Metastases. J Clin Oncol 59(33):5344-51, 11/2008. e-Pub 10/2008. PMID: 18936472.
9. Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26(32):5254-60, 11/2008. e-Pub 10/2008. PMID: 18854565.
10. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, Abbruzzese JL, Ajani JA, Wolff RA. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 113(8):2038-45, 10/2008. PMID: 18759326.
11. Overman MJ, Kopetz S, Varadhachary G, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff P, Xiong H, Abbruzzese JL. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest 26(8):794-9., 10/2008. PMID: 18798063.
12. Overman MJ, Varadhachary G, Kopetz S, Thomas MB, Fukushima M, Kuwata K, Mita A, Wolff RA, Hoff PM, Xiong H, Abburzzese JL. Phase I study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest. New Drugs 26(5), 10/2008. e-Pub 6/2008. PMID: 18528634.
13. Hoff PM, Kopetz S, Thomas MB, Langleben A, Rinaldi D, Anthony L, Wolff RA, Lassere Y, Abbruzzese JL. A phase II study of UFT with leucovorin administered as a twice daily schedule in the treatment of patients with metastatic colorectal cancer. Br J Cancer 99(5):722-6, 9/2008. e-Pub 8/2008. PMID: 18728662.
14. Overman MJ, Fogelman D, Al-Kali A, Crane CH, Evans D, Abdalla EK, Pisters P, Kopetz S, Eng C, Wolff RA. Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. Clin Colorectal Cancer 7(5):338-42, 9/2008. PMID: 18794067.
15. Kauffman CR, Mahvash A, Kopetz S, Wolff RA, Ensor J, Wallace MJ. Partial splenic embolization for cancer patients with thrombocytopenia requiring systemic chemotherapy. Cancer 14(10):2283-8, 5/2008. PMID: 18344210.
16. Kopetz S, Overman M, Chang DZ, Glover KY, Shureiqi I, Wolff RA, Abbruzzese JL, Eng C. Systematic Survey of Therapeutic Trials for Metastatic Colorectal Cancer: Room for Improvement in the Critical Pathway. J Clin Oncol 26(12):2000-5, 4/2008. PMID: 18421052.
17. Kopetz S, Freitas D, Calabrichi A, Hoff PM. Adjuvant Chemotherapy for Stage II Colon Cancer. Oncology 22(3):260-70, 3/2008. PMID: 18494354.
18. Dhillon N, Kopetz S, Pei BL, Fabbro ED, Zhang T, Bruera E. Clinical findings of a palliative care consultation team at a comprehensive cancer center. J Palliat Med 11(2):191-7, 3/2008. PMID: 18333733.
19. Kopetz S. Novel Targets for Systemic Therapy of Colorectal Cancer. Clin Adv Hematol Oncol 6(1):38-40, 1/2008. PMID: 18322439.
20. Politano S, Overman M, Pathak P, Chadha R, Glover K, Chang DZ, Wolff RA, Hoff PM, Abbruzzese J, Eng C, Kopetz S. Second-Line Chemotherapy Use in Metastatic Colon Cancer Varies by Disease Responsiveness. Clin Colorectal Cancer 1(1):55-9, 1/2008. PMID: 18279578.
21. Kopetz S, Shah AN, Gallick GE. SRC continues aging: current and future clinical directions. Clin Cancer Res 13(24)(24):7232-6, 12/2007. PMID: 18094400.
22. Chun YS, Vauthey JN, Ribero D, Donadon M, Mullen JT, Eng C, Madoff DC, Chang DZ, Ho L, Kopetz S, Wei SH, Curley SA, Abdalla EK. Systemic Chemotherapy and Two-Stage Hepatectomy for Extensive Bilateral Colorectal Liver Metastases: Perioperative Safety and Survival. J Gastrointest Surg 11(11):1498-1505, 11/2007. e-Pub 9/2007. PMID: 17849166.
23. Kopetz S. Targeting Src and Epidermal Growth Factor Receptor in Colorectal Cancer: Rationale and Progress Into the Clinic. Gastrointestinal Cancer Research 1(4):S37-41, 7/2007.
24. Kopetz S, Jimenez C, Tu SM, Sharma P. Pulmonary arteriovenous fistula in a patient with renal cell carcinoma. Eur Respir J 29(4):813-5, 12/2006. PMID: 17400880.
25. Kopetz S, Hoff PM. Cytotoxic chemotherapy for advanced colorectal cancer. Recent advances in management. Oncology (Williston Park) 19(13)(13 Suppl 6):11-7, 11/2005. PMID: 16502665.
26. Kopetz S. Endothelin-1 as a Target For Therapeutic Intervention in Prostate Cancer. Invest New Drugs 20(2):173-82, 5/2002. PMID: 12099577.
27. Kopetz ES, TH Magnuson, MD Duncan, JS Bender, KD Lillemoe, TA Gordon, JL Cameron, JW Harmon. Complications of neglected cholelithiasis account for significant surgical mortality in the elderly. Surg Forum(52):489-91, 10/2000.
28. Kopetz S, Steele CD, Brandt J, Baker A, Kronberg M, Galik E, Steinberg M, Warren A, Lyketsos CG. Characteristics and outcomes of dementia residents in an assisted living facility. Int J Geriatr Psychiatry 15(7)(7):586-93, 7/2000. PMID: 10918338.
29. Cheng MD, Nash TM, Kopetz ES. Retrieval of Aerosol Optical Thickness by Means of the Least-Median-Squares Robust Algorithm. Journal of Aerosol Science 30(6):805-17, 1/1999.
30. Walczak WJ, Xiao JM, Kopetz ES, Lease K, Grau H, Lee SP, Han MK, and Knutson JR. Golden Ruler: Very Long-Range Resonance Energy Transfer to Surface Plasmon Acceptors. Biophysical Journal, 72:367, 2/1997.

Grant & Contract Support

Title: MicroRNAs and other non-coding RNAs in colorectal metastasis, RO1
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Calin
Duration: 6/8/2009 - 6/7/2011
 
Title: Src Inhibition in Colorectal Cancer, K23
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 9/1/2008 - 8/30/2013
 
Title: Career Development Award
Funding Source: American Society of Clinical Oncology (ASCO)
Role: Principal Investigator
Duration: 7/1/2008 - 1/1/2011
 
Title: Preclinical strategies for selection of patients with metastatic colon cancer susceptible to AZD0530 in combination with chemotherapy
Funding Source: AstraZeneca
Role: Co-Principal Investigator
Principal Investigator: Gary Gallick
Duration: 6/30/2008 - 5/31/2010
 
Title: Targeted Assessment of Antiangiogenic Therapy
Funding Source: NIH/NCI
Role: Project Leader
Principal Investigator: James Abbruzzese
Duration: 1/1/2007 - 12/31/2008
 
Title: NIH Extramural Loan Repayment Program
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2006 - present
 
Title: K12, Paul Calabresi Career Development Award for Clinical Oncology (Fellow: 2006-07, Faculty 2007-08)
Funding Source: NIH/NCI
Role: Investigator
Duration: 9/1/2005 - 8/30/2008
 
Title: Graduate Program in Cancer Metastasis Research: From Bench to Bedside
Funding Source: UT Graduate Program Initiative
Role: Collaborator
Principal Investigator: Gallick

Last updated: 9/1/2009